Pharmaceuticals

The FDA grants PolyPid a crucial $4.3 million fee waiver for its D-PLEX₁₀₀ drug, freeing up vital cash to accelerate its commercial launch.

Consumers overcharged for generic drugs may get cash from a new $17.8M settlement. Find out if you're eligible and how this fits into a larger legal war.

Boston-based PhaseV unveils its AI Conductor, a new platform designed to automate the entire clinical trial lifecycle and accelerate FDA submissions.

After regaining Nasdaq compliance, Incannex Healthcare is leveraging its $75M war chest to advance novel treatments for sleep apnea and anxiety.

A new collaboration will use Voro's 'masking' technology to create tumor-activated ADCs, aiming to make powerful cancer therapies safer and more effective.

Galectin Therapeutics adds legendary neurosurgeon Dr. Henry Brem to its board, a strategic move to leverage his drug development expertise for its lead liver drug.

Exiting stealth, PerturbAI releases an 8-million-cell map of gene function in a living brain, aiming to slash the cost and time of creating new drugs.

Backed by dialysis giants DaVita and U.S. Renal Care, a new startup licenses a first-in-class therapy to transform treatment for kidney patients.

A new telehealth model challenges the prescription-first approach, combining GLP-1s with 24/7 clinical support. Is this the future of metabolic health?

UK biotech Alchemab hires Sanofi's Ulrich Wendt as CBO to forge major pharma deals for its novel AI platform that mines the secrets of human resilience.

A new alliance aims to overhaul Alzheimer's research, demanding a precision approach for the 65% of patients carrying the high-risk APOE4 gene.

A new compound could make CAR-T cell therapy more durable and less costly, showing promise against both cancer and HIV in groundbreaking new research.

With its lead autoimmune drug nearing FDA review and a new $250M in funding, Zenas BioPharma prepares for a major leap from R&D to market.

Inc. names Tiffany Whitlow to its Female Founders 500, validating Acclinate's model of making inclusive clinical research a profitable, high-growth venture.

Nasus Pharma's NS002 nasal spray reached critical therapeutic levels in half the time of EpiPen, heralding a potential new era for anaphylaxis treatment.

As MediciNova execs meet investors at the ROTH Conference, all eyes are on pivotal updates for its ALS, MS, and NAFLD drug candidates.

New data on an oral Parkinson's drug and major strides in rare disease research signal Lundbeck's deep commitment to tackling complex neurological disorders.

Actelion Pharmaceuticals settles a class action lawsuit for $65M, accused of illegally blocking a cheaper generic for its life-saving hypertension drug.

OTC-listed ProText Mobility unveils an audacious plan to tokenize biotech assets, partner with major banks, and uplist to a major exchange. Can it deliver?

As AI chips push power and heat limits, Compal debuts its "ONE Integrated Solution" at GTC 2026, a unified rack system aimed at defining the future of data centers.